Method and kit for capturing fetal nucleated red blood cells

Through the combination of magnetic bead-labeled antibodies and fluorescent labeling reagents, the capture rate and accuracy of fetal nucleated red blood cells is improved, and the problem of low capture rate and accuracy in non-invasive prenatal diagnosis is solved, and the reliability of the diagnosis is improved.

CN118956744APending Publication Date: 2024-11-15BEIJING ANGEL GENE MEDICAL TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410885739.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-03
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

Among the existing non-invasive prenatal diagnosis methods, the capture rate and capture accuracy of fetal nucleated red blood cells are difficult to meet the ideal standards, mainly because they are rare in the peripheral blood of pregnant women, which affects the accuracy of disease detection.

Method used

Magnetic bead-labeled antibodies, including magnetic bead-labeled CD71 antibody, magnetic bead-labeled CD147 antibody and magnetic bead-labeled CD36 antibody, capture fetal nucleated red blood cells by specific binding and bind to fluorescent labeling reagents to improve detection visibility.

Benefits of technology

It significantly improves the capture rate and capture accuracy of fetal nucleated red blood cells, ensures the accuracy and reliability of prenatal diagnosis, and reduces the risk to pregnant women and fetus.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118956744A_ABST
    Figure CN118956744A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field related to cell biological detection, in particular to a method and a kit for capturing fetal nucleated red blood cells. The method for capturing the fetal nucleated red blood cells comprises the following steps: S1, capturing the fetal nucleated red blood cells by utilizing specific binding of a magnetic bead labeled antibody and the fetal nucleated red blood cells in a peripheral blood sample to be detected; wherein the magnetic bead labeled antibodies comprise a magnetic bead labeled CD71 antibody, a magnetic bead labeled CD147 antibody and a magnetic bead labeled CD36 antibody. The fetal nucleated red blood cells in the to-be-detected sample are captured through the magnetic bead labeled CD71 antibody, the magnetic bead labeled CD147 antibody and the magnetic bead labeled CD36 antibody, and the capture rate and the capture accuracy of the fetal nucleated red blood cells are improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the technical field related to cell biology detection, and specifically to a method and a kit for enriching fetal nucleated red blood cells. Background Art

[0002] Birth defects are an important factor affecting the quality of the newborn population in my country. Birth defects are related to individual, environmental and genetic factors of pregnant women. Among them, prenatal diagnosis, as an important part of secondary prevention of birth defects, plays a key role in determining the birth of fetuses with genetic diseases. Therefore, prenatal diagnosis uses advanced molecular diagnostic technology to establish safe and effective prenatal diagnostic methods and a stable detection system, which is the fundamental way to reduce the birth of children with congenital genetic diseases and improve the quality of the population. The gold standard for prenatal diagnosis in clinical practice is genetic testing by methods such as amniocentesis and chorionic villus sampling. Although the diagnostic results of these methods are accurate and reliable, they all use invasive detection methods. Not only are there unavoidable risks such as miscarriage and infection, but the detection time is late and the cycle is long, which can also cause harm to pregnant women. There is a risk of intrauterine infection and miscarriage for pregnant women and fetuses. Therefore, the field of non-invasive prenatal diagnosis is one of the main directions of development at present.

[0003] The use of fetal components in maternal peripheral blood for molecular biology or genetic analysis and diagnosis is an important part of non-invasive prenatal genetic testing (NIPT), where the fetal components in maternal peripheral blood include: cell-free fetal DNA (cffDNA), fetal nucleated red blood cells (FNRBCs), etc. Among them, cffDNA is essentially a small DNA fragment with incomplete genetic information, and it will be chimerized with the mother's DNA fragment. It cannot be used to detect mosaicism, Robert's translocation, single gene diseases, etc., and its clinical application is subject to many restrictions. As one of the most promising candidates for noninvasive prenatal diagnosis, FNRBCs have many characteristics: (1) There are no nucleated red blood cells in the peripheral blood of normal people. If they do exist, it is a pathological phenomenon, and the cell morphology is different from that of normal cells; (2) FNRBCs have a nuclear structure that carries all the genetic information of the fetus and proteomic information; (3) There are a variety of relatively specific antigens on the cell membrane surface of FNRBCs, such as CD71, CD36, glycophorin A (Glycophorin A, GPA, CD235a) and fetal hemoglobin (HbF, γ, ε, ζ peptide chains); (4) FNRBCs have a limited life cycle and will be completely cleared within 3 months after delivery. When used for prenatal diagnosis, they are not affected by the previous pregnancy.

[0004] Although FNRBCs are the best candidate cells for NIPT, the main problem they face in clinical practice is that the capture rate and capture accuracy are difficult to reach the ideal standard. FNRBCs are rare in the peripheral blood of pregnant women, with only a few to dozens of FNRBCs per milliliter of maternal peripheral blood. Summary of the invention

[0005] In view of this, in order to improve the capture rate and capture accuracy of fetal nucleated red blood cells, the present application provides a method and a kit for capturing fetal nucleated red blood cells.

[0006] In a first aspect of the present application, the present application provides a method for capturing fetal nucleated red blood cells, the method comprising the following steps:

[0007] S101. Utilize magnetic bead-labeled antibodies to specifically bind to fetal nucleated red blood cells in the sample to be tested to capture fetal nucleated red blood cells; wherein the magnetic bead-labeled antibodies include magnetic bead-labeled CD71 antibodies, magnetic bead-labeled CD147 antibodies, and magnetic bead-labeled CD36 antibodies.

[0008] In some optional embodiments, in step S101, the order of specific binding of the magnetic bead-labeled antibodies to the fetal nucleated red blood cells is magnetic bead-labeled CD71 antibody, magnetic bead-labeled CD147 antibody, and magnetic bead-labeled CD36 antibody.

[0009] In some optional embodiments, the sample to be tested is selected from a peripheral blood sample or an amniotic fluid sample.

[0010] In some optional embodiments, the particle size of the magnetic beads in the magnetic bead-labeled antibody is selected from 250 to 350 nm; and / or the PDI value of the magnetic beads in the magnetic bead-labeled antibody is ≤0.5.

[0011] In some optional embodiments, in step S101, before using magnetic beads to label antibodies and specifically bind to fetal nucleated red blood cells in the sample to be tested, the sample to be tested is also filtered through a whole blood membrane and centrifuged.

[0012] In some optional implementation schemes, the operation process of step S101 includes the following steps:

[0013] S101-1, the sample to be tested passes through a whole blood filter membrane and is centrifuged; thereafter, the retentate on the whole blood filter membrane is resuspended to obtain a retentate resuspension solution;

[0014] S101-2, adding magnetic bead-labeled CD71 antibody to the resuspension of the retentate obtained in step S101-1, and performing incubation and magnetic separation to obtain a conjugate and suspension of magnetic bead-labeled CD71 antibody and fetal nucleated red blood cells;

[0015] S101-3, adding magnetic bead-labeled CD147 antibody to the suspension obtained in step S101-2, and performing incubation and magnetic separation to obtain a conjugate and suspension of magnetic bead-labeled CD147 antibody and fetal nucleated red blood cells;

[0016] S101-4. Add magnetic bead-labeled CD36 antibody to the suspension obtained in step S101-3, and obtain a conjugate of magnetic bead-labeled CD36 antibody and fetal nucleated red blood cells through incubation and magnetic separation.

[0017] In some optional embodiments, the method further comprises the following steps:

[0018] S102, labeling the fetal nucleated red blood cells captured in step S101 with a fluorescent labeling reagent.

[0019] In some optional embodiments, the fluorescent labeling reagent comprises 4',6-diamidino-2-phenylindole dihydrochloride, fluorescein isothiocyanate and phycoerythrin.

[0020] In some optional implementations, the operation process of step S102 includes the following steps:

[0021] S102-1, preparing the fluorescent labeling reagent;

[0022] S102-2, respectively add the fluorescent labeling reagent obtained in step S102-1 to the conjugate of magnetic beads labeled CD71 antibody and fetal nucleated red blood cells obtained in step S101-2, the conjugate of magnetic beads labeled CD147 antibody and fetal nucleated red blood cells obtained in step S101-3, and the conjugate of magnetic beads labeled CD36 antibody and fetal nucleated red blood cells obtained in step S101-4, and obtain three resuspensions after light-proof staining, magnetic separation and resuspension; then, drop the three resuspensions on the same glass slide and dry them to obtain a glass slide with captured fetal nucleated red blood cells.

[0023] In the second aspect of the present application, the present application provides a kit for capturing fetal nucleated red blood cells according to the method described in the first aspect of the present application, the kit comprising a magnetic bead-labeled antibody and a fluorescent labeling reagent;

[0024] Wherein, the magnetic bead-labeled antibodies include magnetic bead-labeled CD71 antibodies, magnetic bead-labeled CD147 antibodies, and magnetic bead-labeled CD36 antibodies;

[0025] The fluorescent labeling reagent comprises 4',6-diamidino-2-phenylindole dihydrochloride staining solution, fluorescein isothiocyanate staining solution and phycoerythrin staining solution.

[0026] This application has the following beneficial effects:

[0027] First, the present application captures fetal nucleated red blood cells in the sample to be tested by magnetic bead-labeled CD71 antibody, magnetic bead-labeled CD147 antibody and magnetic bead-labeled CD36 antibody, which not only improves the capture rate of fetal nucleated red blood cells, but also improves the capture accuracy of fetal nucleated red blood cells.

[0028] Second, the present application captures fetal nucleated red blood cells in the sample to be tested in the order of magnetic bead-labeled CD71 antibody, magnetic bead-labeled CD147 antibody and magnetic bead-labeled CD36 antibody, which can further improve the capture rate and capture accuracy of fetal nucleated red blood cells. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] Figure 1 It is a fluorescent photograph of FNRBCs captured under a fluorescence microscope of the five groups of samples to be tested in Example 1; in the figure, 10 represents the first group of samples to be tested, 50 represents the second group of samples to be tested, 100 represents the third group of samples to be tested, 200 represents the fourth group of samples to be tested, and 500 represents the fifth group of samples to be tested.

[0030] Figure 2 It is the counting result of FNRBCs captured by the five groups of samples to be tested under a fluorescence microscope in Example 1; in the figure, 10 represents the first group of samples to be tested, 50 represents the second group of samples to be tested, 100 represents the third group of samples to be tested, 200 represents the fourth group of samples to be tested, and 500 represents the fifth group of samples to be tested.

[0031] Figure 3 These are fluorescent photographs of FNRBCs captured under a fluorescent microscope in Comparative Examples 1 to 3; in the figure, 1 represents Comparative Example 1, 2 represents Comparative Example 2, and 3 represents Comparative Example 3. DETAILED DESCRIPTION

[0032] The present application discloses a method and a kit for capturing fetal nucleated red blood cells. Those skilled in the art can refer to the content of this article and appropriately improve the process parameters to achieve it. It should be particularly noted that all similar substitutions and modifications are obvious to those skilled in the art, and they are all deemed to be included in this application. The methods and applications of this application have been described through preferred embodiments, and relevant personnel can obviously modify or appropriately change and combine the methods and applications described herein without departing from the content, spirit and scope of this application to implement and apply the technology of this application.

[0033] Explanation of terms

[0034] The "PDI" used in this application refers to the Polydispersity Index, which is a parameter that describes the uniformity of particle size distribution. The smaller the PDI value, the more uniform the particle size distribution; conversely, the larger the PDI value, the more uneven the particle size distribution.

[0035] Method for capturing fetal nucleated red blood cells

[0036] In a first aspect of the present application, the present application provides a method for capturing fetal nucleated red blood cells, the method comprising the following steps:

[0037] S101. Utilize magnetic bead-labeled antibodies to specifically bind to fetal nucleated red blood cells in the sample to be tested to capture fetal nucleated red blood cells; wherein the magnetic bead-labeled antibodies include magnetic bead-labeled CD71 antibodies, magnetic bead-labeled CD147 antibodies, and magnetic bead-labeled CD36 antibodies.

[0038] In some optional embodiments, in step S101, the order of specific binding of the magnetic bead-labeled antibodies to the fetal nucleated red blood cells is magnetic bead-labeled CD71 antibody, magnetic bead-labeled CD147 antibody, and magnetic bead-labeled CD36 antibody, in that order.

[0039] In some optional embodiments, the sample to be tested is selected from a peripheral blood sample or an amniotic fluid sample.

[0040] In some optional embodiments, the particle size of the magnetic beads in the magnetic bead-labeled antibody is selected from 250 to 350 nm; for example, 250 nm, 260 nm, 270 nm, 280 nm, 290 nm, 300 nm, 310 nm, 320 nm, 330 nm, 340 nm or 350 nm, etc.

[0041] In some optional embodiments, the PDI value of the magnetic beads in the magnetic bead-labeled antibody is ≤0.5; for example, 0.1, 0.2, 0.3, 0.4 or 0.5, etc.

[0042] In some optional embodiments, in step S101, before using magnetic beads to label antibodies and specifically bind to fetal nucleated red blood cells in the sample to be tested, the sample to be tested is also filtered through a whole blood membrane and centrifuged.

[0043] In some optional implementation schemes, the operation process of step S101 includes the following steps:

[0044] S101-1, the sample to be tested passes through a whole blood filter membrane and is centrifuged; thereafter, the retentate on the whole blood filter membrane is resuspended to obtain a retentate resuspension;

[0045] S101-2, adding magnetic bead-labeled CD71 antibody to the resuspension of the retentate obtained in step S101-1, and performing incubation and magnetic separation to obtain a conjugate and suspension of magnetic bead-labeled CD71 antibody and fetal nucleated red blood cells;

[0046] S101-3, adding magnetic bead-labeled CD147 antibody to the suspension obtained in step S101-2, and performing incubation and magnetic separation to obtain a conjugate and suspension of magnetic bead-labeled CD147 antibody and fetal nucleated red blood cells;

[0047] S101-4. Add magnetic bead-labeled CD36 antibody to the suspension obtained in step S101-3, and obtain a conjugate of magnetic bead-labeled CD36 antibody and fetal nucleated red blood cells through incubation and magnetic separation.

[0048] In some optional embodiments, in step S101-1, the centrifugal rotation speed is 800-1200 rpm; for example, 800 rpm, 850 rpm, 900 rpm, 950 rpm, 1000 rpm, 1050 rpm, 1100 rpm, 1150 rpm or 1200 rpm, etc.

[0049] In some optional embodiments, in step S101-1, the centrifugation time is 2 to 5 min; for example, 2 min, 2.5 min, 3 min, 3.5 min, 4 min, 4.5 min or 5 min, etc.

[0050] In some optional embodiments, the method further comprises the following steps:

[0051] S102, labeling the fetal nucleated red blood cells captured in step S101 with a fluorescent labeling reagent.

[0052] In some optional embodiments, the fluorescent labeling reagent comprises 4',6-diamidino-2-phenylindoledihydrochloride (DAPI, CAS No. 28718-90-3), fluorescein 5-isothiocyanate (FITC, CAS No. 3326-32-7) and phycoerythrin (PE, CAS No. 11016-17-4).

[0053] Among them, DAPI is a blue fluorescent dye that can penetrate the cell membrane. When DAPI combines with double-stranded DNA, it can produce fluorescence that is more than 20 times stronger than DAPI itself. The maximum excitation wavelength of DAPI is 340nm, and the maximum emission wavelength is 488nm; after DAPI combines with double-stranded DNA, the maximum excitation wavelength is 364nm, and the maximum emission wavelength is 454nm. FITC is a green fluorescent derivative, and its isothiocyanate group can react with the amino terminus or primary amine of the protein to achieve protein labeling including antibodies and lectins. The molecular weight of PE is 240,000 Daltons and the extinction coefficient is 1,500,000 cm -1 M -1 , quantum yield (Φ) is 0.84. PE is greatly excited at 565nm (secondary maximum at 495nm) and emits at 573nm, which is in the yellow-orange region of the visible spectrum. It is worth noting that PE and R-PE can be used interchangeably in this application.

[0054] In some optional embodiments, the concentration of 4',6-diamidino-2-phenylindole dihydrochloride in the fluorescent labeling reagent is 0.5-10ug / mL; for example, 0.5ug / mL, 1ug / mL, 1.5ug / mL, 2ug / mL, 2.5ug / mL, 3ug / mL, 3.5ug / mL, 4ug / mL, 4.5ug / mL, 5ug / mL, 5.5ug / mL, 6ug / mL, 6.5ug / mL, 7ug / mL, 7.5ug / mL, 8ug / mL, 8.5ug / mL, 9ug / mL, 9.5ug / mL or 10ug / mL, etc.

[0055] In some optional embodiments, the concentration of fluorescein isothiocyanate in the fluorescent labeling reagent is 0.5-10ug / mL; for example, 0.5ug / mL, 1ug / mL, 1.5ug / mL, 2ug / mL, 2.5ug / mL, 3ug / mL, 3.5ug / mL, 4ug / mL, 4.5ug / mL, 5ug / mL, 5.5ug / mL, 6ug / mL, 6.5ug / mL, 7ug / mL, 7.5ug / mL, 8ug / mL, 8.5ug / mL, 9ug / mL, 9.5ug / mL or 10ug / mL, etc.

[0056] In some optional embodiments, the concentration of phycoerythrin in the fluorescent labeling reagent is 0.5-10ug / mL; for example, 0.5ug / mL, 1ug / mL, 1.5ug / mL, 2ug / mL, 2.5ug / mL, 3ug / mL, 3.5ug / mL, 4ug / mL, 4.5ug / mL, 5ug / mL, 5.5ug / mL, 6ug / mL, 6.5ug / mL, 7ug / mL, 7.5ug / mL, 8ug / mL, 8.5ug / mL, 9ug / mL, 9.5ug / mL or 10ug / mL, etc.

[0057] In some optional implementations, the operation process of step S102 includes the following steps:

[0058] S102-1, preparing the fluorescent labeling reagent;

[0059] S102-2, respectively add the fluorescent labeling reagent obtained in step S102-1 to the conjugate of magnetic beads labeled CD71 antibody and fetal nucleated red blood cells obtained in step S101-2, the conjugate of magnetic beads labeled CD147 antibody and fetal nucleated red blood cells obtained in step S101-3, and the conjugate of magnetic beads labeled CD36 antibody and fetal nucleated red blood cells obtained in step S101-4, and obtain three resuspensions after light-proof staining, magnetic separation and resuspension; then, drop the three resuspensions on the same glass slide and dry them to obtain a glass slide with captured fetal nucleated red blood cells.

[0060] In some optional embodiments, the fluorescent labeling reagent is prepared from 4',6-diamidino-2-phenylindole dihydrochloride staining solution (DAPI staining solution), fluorescein isothiocyanate staining solution (FITC staining solution) and phycoerythrin staining solution (PE staining solution).

[0061] Kit for capturing fetal nucleated red blood cells

[0062] In the second aspect of the present application, the present application provides a kit for capturing fetal nucleated red blood cells according to the method described in the first aspect of the present application, the kit comprising a magnetic bead-labeled antibody and a fluorescent labeling reagent;

[0063] Wherein, the magnetic bead-labeled antibodies include magnetic bead-labeled CD71 antibodies, magnetic bead-labeled CD147 antibodies, and magnetic bead-labeled CD36 antibodies;

[0064] The fluorescent labeling reagent comprises 4',6-diamidino-2-phenylindole dihydrochloride staining solution, fluorescein isothiocyanate staining solution and phycoerythrin staining solution.

[0065] In order to make the purpose, technical solutions and advantages of the present application clearer, the implementation scheme of the present application will be further described in detail below in conjunction with examples.

[0066] Embodiment and comparative example of the method for capturing fetal nucleated red blood cells:

[0067] Example 1

[0068] Example 1 The method for capturing fetal nucleated red blood cells specifically comprises the following steps:

[0069] S101, using magnetic beads to label antibodies and specifically bind to fetal nucleated red blood cells in the sample to be tested to capture fetal nucleated red blood cells. The specific operation process is:

[0070] S101-1. The sample to be tested (5 mL) is passed through the whole blood filter membrane and centrifuged (1000 rpm, 3 min). The whole blood filter membrane is rinsed with PBS buffer three times (1 ml each time). The retained material on the whole blood filter membrane is transferred to the first EP tube, and PBS buffer (5 mL) is added to the first EP tube.

[0071] S101-2, add CD71 immune lipid magnetic spheres (10 μL) to the first EP tube in step S101-1, and incubate at room temperature for 20 min (shake once every 5 min); place the first EP tube on a magnetic separation rack for magnetic separation for 15 min; use a rubber-tipped dropper to absorb the liquid in the first EP tube, and transfer the absorbed liquid to the second EP tube; then, add PBS buffer (1 ml) to the first EP tube and place the first EP tube on a magnetic separation rack for magnetic separation for 5 min, and use a rubber-tipped dropper to absorb and discard the liquid in the first EP tube;

[0072] S101-3, add CD147 immune lipid magnetic spheres (10 μL) to the second EP tube in step S101-2, and incubate at room temperature for 20 min (shake once every 5 min); place the second EP tube on a magnetic separation rack for magnetic separation for 15 min; use a rubber-tipped dropper to absorb the liquid in the second EP tube, and transfer the absorbed liquid to a third EP tube; then, add PBS buffer (1 ml) to the second EP tube and place the second EP tube on a magnetic separation rack for magnetic separation for 5 min, and use a rubber-tipped dropper to absorb and discard the liquid in the second EP tube;

[0073] S101-4. Add CD36 immune lipid magnetic beads (10 μL) to the third EP tube in step S101-3, and incubate at room temperature for 20 min (shake once every 5 min); place the third EP tube on a magnetic separation rack for magnetic separation for 15 min; use a rubber-tipped dropper to aspirate the liquid in the third EP tube and discard it; then, add PBS buffer (1 ml) to the third EP tube and place the third EP tube on a magnetic separation rack for magnetic separation for 5 min, and use a rubber-tipped dropper to aspirate and discard the liquid in the third EP tube.

[0074] S102, using a fluorescent labeling agent to label the fetal nucleated red blood cells captured in step S101. The specific operation process is as follows:

[0075] S102-1, DAPI staining solution (concentration 10ug / mL), FITC staining solution (concentration 10ug / mL) and PE staining solution (concentration 10ug / mL) are mixed evenly to obtain a fluorescent labeling reagent; wherein the DAPI staining solution, the FITC staining solution and the PE staining solution are prepared in a volume ratio of 1:1:1;

[0076] S102-2, respectively remove the first EP tube of step S101-2, the second EP tube of step S101-3, and the third EP tube of step S101-4 from the magnetic separation rack, and add the fluorescent labeling reagent (20 μL) of step S201 to each EP tube and ensure that the magnetic ball is immersed in the fluorescent labeling reagent, and stain for 20 minutes in the dark; after the staining is completed, add double distilled water (1 mL) to each EP tube and place it on the magnetic separation rack, let it stand for 5 minutes, and use a rubber-tipped dropper to absorb the waste liquid in each EP tube; then, add double distilled water (20 μL) to each EP tube, and drop the contents of each EP tube onto the same slide, and count the captured FNRBCs under a fluorescence microscope after drying.

[0077] Among them, for five groups of samples to be tested, the capture efficiency of fetal nucleated red blood cells in this embodiment is verified. Among them, the first group of samples to be tested is to put 10 K562 cells into PBS buffer (5mL); the second group of samples to be tested is to put 50 K562 cells into PBS buffer (5mL); the third group of samples to be tested is to put 100 K562 cells into PBS buffer (5mL); the fourth group of samples to be tested is to put 200 K562 cells into PBS buffer (5mL); the fifth group of samples to be tested is to put 500 K562 cells into PBS buffer (5mL).

[0078] The fluorescence photos of FNRBCs captured by the five groups of samples to be tested under a fluorescence microscope in Example 1 are as follows: Figure 1 The counting results are shown in Table 1 and Figure 2 shown.

[0079] Table 1 Counting results of FNRBCs captured by five groups of samples under fluorescence microscope in Example 1

[0080]

[0081] from Figures 1-2 As can be seen from Table 1, the samples to be tested in the present application sequentially passed through CD71 immunolipid magnetic spheres, CD147 immunolipid magnetic spheres, and CD36 immunolipid magnetic spheres, all of which had a high capture efficiency for K562 cells in each concentration gradient, and the capture efficiency was above 93%.

[0082] Embodiments 2 to 6

[0083] The samples to be tested in Examples 2 to 6 are the third group of samples to be tested.

[0084] Examples 2 to 6 Methods for capturing fetal nucleated red blood cells: Compared with Example 1, the only difference between Examples 2 to 6 is that the order of using CD71 immunolipid magnetic spheres, CD147 immunolipid magnetic spheres, and CD36 immunolipid magnetic spheres is different.

[0085] Table 2 Counting results of FNRBCs captured under a fluorescence microscope in Examples 1 to 6

[0086]

[0087] It can be seen from Table 2 that the order of using CD71 immunolipid magnetic spheres, CD147 immunolipid magnetic spheres, and CD36 immunolipid magnetic spheres in this application affects the capture efficiency; among them, the capture efficiency is optimal when CD71 immunolipid magnetic spheres, CD147 immunolipid magnetic spheres, and CD36 immunolipid magnetic spheres are used in sequence.

[0088] Comparative Example 1

[0089] The samples to be tested in Comparative Example 1 are the third group of samples to be tested.

[0090] Comparative Example 1 Method for capturing fetal nucleated red blood cells: Compared with Example 1, the difference of Comparative Example 1 is only step S101-1. The specific process of step S101-1 in Comparative Example 1 is as follows: the sample to be tested passes through the filter membrane and is centrifuged (1000rpm, 3min), the whole blood filter membrane is rinsed three times with PBS buffer (1ml each time), and the retained material on the filter membrane is moved to the fourth EP tube; CD45 magnetic beads (10μL) are added to the fourth EP tube, and incubated at room temperature for 20min (shaking once every 5min); the fourth EP tube is placed on a magnetic separation rack for magnetic separation for 15min; the liquid in the fourth EP tube is sucked with a rubber-tipped dropper, and the sucked liquid is moved to the first EP tube.

[0091] Comparative Example 2

[0092] The samples to be tested in Comparative Example 2 are the third group of samples to be tested.

[0093] Comparative Example 2 Method for capturing fetal nucleated red blood cells: Compared with Example 1, the difference of Comparative Example 2 is only in step S101-1. The specific process of step S101-1 in Comparative Example 2 is: directly placing the sample to be detected in the first EP tube.

[0094] Comparative Example 3

[0095] The sample to be tested in Comparative Example 3 was PBS buffer (5 mL), ie, the blank control group sample.

[0096] Comparative Example 3: The method for capturing fetal nucleated red blood cells is the same as that of Example 1.

[0097] The fluorescence photos of FNRBCs captured under a fluorescence microscope in Comparative Examples 1 to 3 are as follows: Figure 3 shown.

[0098] Table 3 Counting results of FNRBCs captured under a fluorescence microscope in Example 1 and Comparative Examples 1 to 3

[0099] project Samples to be tested Number of cells added Number of recovered cells Capture efficiency Example 1 Group 3 100 93 93% Comparative Example 1 Group 3 100 72 72% Comparative Example 2 Group 3 100 85 85% Comparative Example 3 Blank control group samples 0 0 —

[0100] It can be seen from Table 3 that after the sample to be tested is filtered through the membrane and before it is captured by CD71 immunolipid magnetic spheres, CD147 immunolipid magnetic spheres, and CD36 immunolipid magnetic spheres in sequence, the CD45 magnetic bead negative sorting process will take away some positive cells, greatly reducing the capture efficiency.

[0101] The samples to be tested were not filtered through the membrane and were directly captured by CD71 immunolipid magnetic spheres, CD147 immunolipid magnetic spheres, and CD36 immunolipid magnetic spheres in sequence, which also significantly reduced the capture efficiency.

[0102] It can be seen that the present application is first filtered through a membrane and then captured in sequence by CD71 immunolipid magnetic spheres, CD147 immunolipid magnetic spheres, and CD36 immunolipid magnetic spheres, and the capture efficiency is optimal.

[0103] Comparative Example 4

[0104] Comparative Example 4 is a gold standard for the sorting and identification method of capturing fetal nucleated red blood cells, which specifically includes the following steps:

[0105] S201, Production:

[0106] S201-1. Place the sample to be tested (5 mL, such as amniotic fluid sample) in a centrifuge tube and centrifuge, discard the supernatant, add collagenase B (5 mL) to the centrifuge tube for digestion, add balanced salt solution (BSS) (5 mL) and pipette evenly; then, place the centrifuge tube in a 37° C. water bath for 30 min;

[0107] S201-2, centrifuge the centrifuge tube and discard the supernatant, add 0.075M KCl hypotonic solution (5mL) to the centrifuge tube and blow evenly; then, place the centrifuge tube in a 37°C water bath for 30 minutes;

[0108] S201-3. Add Carnoy's fixative (methanol and glacial acetic acid in a volume ratio of 3:1) to the centrifuge tube for fixation three times (15-20 minutes each time), centrifuge and discard the supernatant until the volume is appropriate, then drop the contents of the centrifuge tube onto at least two slides. Aging the slides at room temperature overnight or using a slide oven at 56°C for 30 minutes.

[0109] Verification test

[0110] Samples to be tested: Peripheral blood samples and amniotic fluid samples from a pregnant woman in the middle and late stages of pregnancy from Foshan Maternal and Child Health Hospital in May 2023 were selected. The pregnant woman was pregnant with her third child; among them, the first fetus's heart color Doppler ultrasound at 23+ weeks found that the whole ventricle was enlarged, mainly on the right heart; the second fetus was found to be enlarged at 23+ weeks, and dilated cardiomyopathy was not eliminated; the third fetus was 30+ weeks pregnant, and the prenatal examination B-ultrasound found cardiomyopathy. The pregnant woman has signed an informed consent form for prenatal diagnosis. Among them, the peripheral blood samples were subjected to the methods of Examples 1 to 6, and the amniotic fluid samples were subjected to the methods of Example 1 and Comparative Example 4, respectively, to obtain a slide with captured FNRBCs.

[0111] First, the cells captured on the slide were counted using an OLYMPUSBX51 fluorescence microscope, and the number of cells captured on the slide with FNRBCs captured was y1; then, the Sanger sequencing method was used to identify whether the cells captured on the slide with FNRBCs were fetal nucleated red blood cells, and the number of nucleated red blood cells captured on the slide with FNRBCs captured was y2; finally, the capture accuracy rate P of nucleated red blood cells was calculated, and the calculation formula was:

[0112] The cell origin was confirmed by fluorescence in situ hybridization (FISH) analysis, where the FISH diagnostic criteria were based on the International System for Nomenclature of Human Cell Genomics (ISCN2020).

[0113] The FISH detection process includes the following steps:

[0114] S301, pre-processing:

[0115] S301-1. In a 37°C water bath, mix a 100ug / mL ribonuclease A solution in deionized water (60uL, referred to as RNase A solution) with a 2×SSC buffer (40mL) evenly; then, place the glass slide with captured FNRBCs in it for 30 minutes. During this period, preheat a 0.01M HCl solution in a 37°C water bath (40mL, referred to as HCl solution), and add pepsin storage solution (160uL) to a dry Coplin bottle that has been preheated to 37°C.

[0116] S301-2, rinse the glass slide obtained in step S301-1 in 2×SSC buffer solution at room temperature for 2 times (5 min each time), soak in 0.1M HCl solution for 10 min, and rinse in 2×SSC buffer solution for 2 times (5 min each time);

[0117] S301-3, pour the preheated 0.01M HCl solution in step S301-1 into the Coplin bottle containing the pepsin storage solution in step S301-1 and mix well, place the glass slide obtained in step S301-2 therein, and soak at 37°C for 10 minutes; then, take out the glass slide, and rinse it twice in 2×SSC buffer at room temperature (5 minutes each time);

[0118] S301-4. Place the glass slide obtained in step S301-3 in pre-cooled 70% (v / v) ethanol aqueous solution, 85% (v / v) ethanol aqueous solution, and 100% (v / v) ethanol in turn for dehydration for 3 min each, and dry naturally.

[0119] S302, Denaturation and hybridization:

[0120] S302-1. Prepare FISH probes: prepare 7uL hybridization buffer, 1uL deionized water and 2uL probes (CSP18 / CSPX / CSPY probe set and GLP13 / GLP21 probe set) to obtain a FISH probe mixture; then, denature the FISH probe mixture in a (73±1)°C water bath for 5 minutes, and place it in a 46°C water bath for later use;

[0121] S302-2, placing the glass slide obtained in step S301-4 in a 70% (v / v) deionized formamide denaturing solution at (73±1)°C for 5 minutes and then dehydrating;

[0122] S302-3, drop the FISH probe mixture obtained in step S302-1 onto the hybridization area of ​​the slide obtained in step S302-2, immediately cover it with a cover slip, and seal the edges with rubber glue; then, place it in a wet box preheated to 42°C, and hybridize it in an incubator at 42°C for 16 hours.

[0123] S303, slide washing:

[0124] The coverslip was removed from the slide, and the slide was washed three times (10 min each time) in a 50% (v / v) formamide DMSO-d6 solution, once (10 min each time) in a 2×SSC buffer solution, and once (5 min each time) in an NP-40 lysis buffer (from Amresco). Afterwards, the slide was immersed in a 70% (v / v) ethanol aqueous solution at room temperature for 3 min and the slide was taken out.

[0125] S304, counterstaining:

[0126] The glass slide obtained in step S303 was placed in a dark place to dry naturally, 4',6-diamidino-2-phenylindole dihydrochloride (CAS No. 28718-90-3, referred to as DAPI) counterstain (12uL) was added to the hybridization area of ​​the glass slide, and a coverslip was immediately added, and it was placed in a dark place for 20 minutes; thereafter, a suitable filter set was selected under an OLYMPUSBX51 fluorescence microscope to observe the fluorescence signal, count, photograph, save and analyze the results.

[0127] Among them, the test results are shown in Table 4.

[0128] Table 4 Test results of verification test

[0129]

[0130] As can be seen from Table 4, the present application captures fetal nucleated red blood cells in the sample to be tested by magnetic bead-labeled CD71 antibody, magnetic bead-labeled CD147 antibody and magnetic bead-labeled CD36 antibody, which not only improves the capture rate of fetal nucleated red blood cells, but also improves the capture accuracy of fetal nucleated red blood cells.

[0131] By comparing Examples 1 to 6, it can be seen that the present application captures fetal nucleated red blood cells in the sample to be tested in the order of magnetic bead-labeled CD71 antibody, magnetic bead-labeled CD147 antibody, and magnetic bead-labeled CD36 antibody, which can further improve the capture rate and capture accuracy of fetal nucleated red blood cells.

[0132] The above is a detailed introduction to a method and kit for capturing nucleated red blood cells provided by the present application. This article uses specific examples to illustrate the principles and implementation methods of the present application. The description of the above embodiments is only used to help understand the method and its core idea of ​​the present application. It should be pointed out that for those skilled in the art, without departing from the principles of the present application, several improvements and modifications can be made to the present application, and these improvements and modifications also fall within the scope of protection of the claims of the present application.

Claims

1. A method for capturing fetal nucleated red blood cells, characterized in that: The method comprises the following steps: S101. Utilize magnetic bead-labeled antibodies to specifically bind to fetal nucleated red blood cells in the sample to be tested to capture fetal nucleated red blood cells; wherein the magnetic bead-labeled antibodies include magnetic bead-labeled CD71 antibodies, magnetic bead-labeled CD147 antibodies, and magnetic bead-labeled CD36 antibodies.

2. The method according to claim 1, characterized in that In step S101, the order of specific binding of the magnetic bead-labeled antibodies to the fetal nucleated red blood cells is magnetic bead-labeled CD71 antibody, magnetic bead-labeled CD147 antibody, and magnetic bead-labeled CD36 antibody.

3. The method according to claim 1, characterized in that The sample to be detected is selected from a peripheral blood sample or an amniotic fluid sample.

4. The method according to claim 1, characterized in that: The particle size of the magnetic beads in the magnetic bead-labeled antibody is selected from 250 to 350 nm; and / or The PDI value of the magnetic beads in the magnetic bead-labeled antibody is ≤0.

5.

5. The method according to claim 1, characterized in that In step S101, before the magnetic bead-labeled antibody is used to specifically bind to the fetal nucleated red blood cells in the sample to be detected, the sample to be detected is filtered through a whole blood membrane and centrifuged.

6. The method according to any one of claims 1 to 5, characterized in that: The operation process of step S101 includes the following steps: S101-1, the sample to be tested passes through a whole blood filter membrane and is centrifuged; thereafter, the retentate on the whole blood filter membrane is resuspended to obtain a retentate resuspension solution; S101-2, adding magnetic bead-labeled CD71 antibody to the resuspension of the retentate obtained in step S101-1, and performing incubation and magnetic separation to obtain a conjugate and suspension of magnetic bead-labeled CD71 antibody and fetal nucleated red blood cells; S101-3, adding magnetic bead-labeled CD147 antibody to the suspension obtained in step S101-2, and performing incubation and magnetic separation to obtain a conjugate and suspension of magnetic bead-labeled CD147 antibody and fetal nucleated red blood cells; S101-4. Add magnetic bead-labeled CD36 antibody to the suspension obtained in step S101-3, and obtain a conjugate of magnetic bead-labeled CD36 antibody and fetal nucleated red blood cells through incubation and magnetic separation.

7. The method according to claim 1, characterized in that The method further comprises the following steps: S102, labeling the fetal nucleated red blood cells captured in step S101 with a fluorescent labeling reagent.

8. The method according to claim 7, characterized in that The fluorescent labeling reagent comprises 4',6-diamidino-2-phenylindole dihydrochloride, fluorescein isothiocyanate and phycoerythrin.

9. The method according to any one of claims 7 to 8, characterized in that: The operation process of step S102 includes the following steps: S102-1, preparing the fluorescent labeling reagent; S102-2, respectively add the fluorescent labeling reagent obtained in step S102-1 to the conjugate of magnetic beads labeled CD71 antibody and fetal nucleated red blood cells obtained in step S101-2, the conjugate of magnetic beads labeled CD147 antibody and fetal nucleated red blood cells obtained in step S101-3, and the conjugate of magnetic beads labeled CD36 antibody and fetal nucleated red blood cells obtained in step S101-4, and obtain three resuspensions after light-proof staining, magnetic separation and resuspension; then, drop the three resuspensions on the same glass slide and dry them to obtain a glass slide with captured fetal nucleated red blood cells.

10. A kit for capturing fetal nucleated red blood cells based on the method according to any one of claims 1 to 9, characterized in that: The kit comprises a magnetic bead-labeled antibody and a fluorescent labeling reagent; Wherein, the magnetic bead-labeled antibodies include magnetic bead-labeled CD71 antibodies, magnetic bead-labeled CD147 antibodies, and magnetic bead-labeled CD36 antibodies; The fluorescent labeling reagent comprises 4',6-diamidino-2-phenylindole dihydrochloride staining solution, fluorescein isothiocyanate staining solution and phycoerythrin staining solution.